2024年03月17日 公司深 度研究 公 买入 / 首次 司 惠泰医疗(688617) 研 究 目标价:567.83 昨收盘:454.26 医药生物 医疗器械 “三合一”PFA 进展居前，血管介入矩阵日渐成型 ◼ 走势比较 报告摘要 电生理：集采加速医院准入和手术放量，心脏脉冲消融系统进展居前 50% 随着老龄化程度的加剧、就医条件的改善、患者数量的增加以及患 太 36% 者认知的提高，中国的心脏电生理手术量和市场规模有望持续增长。根 平 22% 据 Frost & Sullivan，预计 2025年中国的心脏电生理手术数量达到 57.46 洋 8% 万例（2021年-2025年的 CAGR为 28.00%），2025年中国心脏电生理器 证 (2( 06 %% ))71/3/32 82/5/32 8/8/32 91/01/32 03/21/32 11/3/42 械市场 20规 17模 -20预 22计 年将 公增 司至 电1 生57 理.26 业亿 务元 从（ 02 .0 92 71 亿年 元-2 增02 长5年 至C 2A .9G 2R 亿为 元2 。4.3 24 0% 22）。 券 年 福建电生理集采中 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2024-007 2024 年 3 月 15 日 公司于 2024 年 3 月 14 日收到苏州启元股权投资管理合伙企业（有限合伙） （以下简称"苏州启元"）发来的《深圳惠泰医疗器械股份有限公司简式权益变 动报告书（修订版）》（信息披露义务人为苏州启元股权投资管理合伙企业（有 限合伙）），具体补充事项如下： 鉴于苏州启元作为本次协议转让中苏州工业园区启华三期投资中心（有限合 伙）（以下简称"启华三期"）、苏州工业园区启明融科股权投资合伙企业（有 限合伙）（以下简称"启明融科"）、苏州启明融盈创业投资合伙企业（有限合 伙）（以下简称"启明融盈"）的私募基金管理人，为启华三期、启明融科和启 明融盈申请开立了用于持有公司股份的证券账户，证券账户名称分别为"苏州启 元股权投资管理合伙企业（有限合伙）－苏州工业园区启华三期投资中心（有限 合伙）"（以下简称"苏州启元－启华三期"）、"苏州启元股权投资管理合伙 企业（有限合伙）－苏州工业园区启明融科股权投资合伙企业（有限合伙）"（以 下简称"苏州启元－启明融科"）、"苏州启元股权投资管理合伙企业（有限合 伙）－苏州启明 ...

深圳惠泰医疗器械股份有限公司 简式权益变动报告书 （修订版） 上市公司名称：深圳惠泰医疗器械股份有限公司 股票上市地点：上海证券交易所 股票简称：惠泰医疗 股份变动性质：股份减少（协议转让） 签署日期：2024 年 3 月 - 1 - 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及其他相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定，本报 告书已全面披露了信息披露义务人在深圳惠泰医疗器械股份有限公司中拥有权 益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在深圳惠泰医疗器械股份有限公司中拥有权益的 股份。 股票代码：688617 信息披露义务 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2024-006 深圳惠泰医疗器械股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）分别于 2023 年 4 月 6 日、2023 年 4 月 27 日召开了第二届董事会第三次会议、2022 年年度股东大会， 审议通过了《关于续聘公司 2023 年度会计师事务所的议案》，同意公司续聘立 信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"）为公司 2023 年度财务报告审计机构。具体内容详见公司于 2023 年 4 月 7 日在上海证券 交易所网站（www.sse.com.cn）披露的《深圳惠泰医疗器械股份有限公司关于续 聘会计师事务所的公告》（公告编号：2023-011）。 近日，公司收到立信会计师事务所发来的《立信会计师事务所（特殊普通合 伙）关于变更深圳惠泰医疗器械股份有限公司 2023 年度签字注册会计师的函》。 现将有关情况公告如下： 一、本次变更项目合伙人及签字 ...

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company's performance in 2023 is in line with expectations, with projected total revenue of 1.651 billion yuan (YOY +35.79%) and a net profit attributable to shareholders of 536 million yuan (YOY +49.61%). This growth is attributed to the company's active expansion in domestic and international markets, increased product coverage, and ongoing technological innovation [2][3] - In Q4 2023, the company expects to achieve revenue of 437 million yuan (YOY +2.6%) and a net profit of 133 million yuan (YOY -8.9%) [2] - The company continues to deepen its market expansion both domestically and internationally, leveraging volume-based procurement to facilitate rapid hospital access. The company has increased its presence in over 800 hospitals and completed more than 3,500 three-dimensional electrophysiological surgeries in over 400 hospitals [2] - The earnings forecast for 2023-2025 indicates EPS of 7.98 yuan, 10.44 yuan, and 14.12 yuan respectively. The company is positioned as a leader in the domestic electrophysiology market, benefiting from volume procurement, with a projected PE of 42X for 2024, corresponding to a fair value of 438.28 yuan per share [2][3] Financial Summary - The company is expected to achieve total revenue of 1.651 billion yuan in 2023, with a growth rate of 35.8% in 2024 and 35.9% in 2025 [6] - The net profit attributable to shareholders is projected to be 534 million yuan in 2023, with growth rates of 49.1% in 2024 and 35.4% in 2025 [6] - The EPS is forecasted to increase from 7.98 yuan in 2023 to 14.12 yuan in 2025, indicating strong growth potential [6][8]

公 司 研 证券研究报告 究 ＃industryId＃ 医药生物 ＃investSuggestion＃ ＃ ＃d惠yCo泰mpa医ny＃疗 （688617.SH ） investSug 增持 ( 维ges持tionC）h 000009 ＃title＃ 各产品线持续增长，迈瑞入主国际化有望登上新台阶 ange＃ ＃createTime1＃ 2024年2月 25日 投资要点 公 ＃市场ma数rk据etData＃ ＃summary＃  近日，惠泰医疗发布2023年业绩快报。2023年，公司实现营业收入16.51 司 日期 2024-02-23 亿元，同比增长35.79%；实现归母净利润5.36亿元，同比增长49.61%； 点 收盘价（元） 419.69 实现扣非归母净利润4.75亿元，同比增长47.64%。2023年单四季度，公 评 总股本（百万股） 66.86 司实现营业收入4.37亿元，同比增长33%；实现归母净利润1.32亿元， 报 流通股本（百万股） 54.35 同比增长36%；实现扣非归母净利润1.15亿元，同比增长29%。 净资产（百万元） 1916.00 告 总资产（百万元） 2597.89  点 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [4][6]. Core Views - The company is expected to maintain high growth in 2023, with a projected net profit of 510-565 million yuan, representing a year-on-year increase of 42.45%-57.81% [3]. - The acquisition of control by Mindray Medical is anticipated to strengthen the company's leading position in the vascular intervention market, enhancing product performance and expanding overseas market access [4]. - The company's three main business segments—electrophysiology, coronary access, and peripheral intervention—are expected to continue high growth due to increased hospital coverage and ongoing product upgrades [6]. Summary by Sections Financial Performance - The company forecasts revenue for 2023, 2024, and 2025 to be 1.672 billion, 2.280 billion, and 3.063 billion yuan, respectively, with corresponding net profits of 539 million, 727 million, and 996 million yuan [6]. - The expected earnings per share (EPS) for the same years are 8.07, 10.88, and 14.89 yuan, with price-to-earnings (P/E) ratios of 49, 36, and 26 times [6]. Market Position and Strategy - The company is actively expanding its market presence through promotional activities and enhancing brand recognition, alongside efforts to penetrate international markets [3]. - The collaboration with Mindray is expected to significantly enhance the company's product capabilities in areas where it has been relatively weak, such as 3D measurement systems and radiofrequency ablation devices [4]. Growth Drivers - Continuous iteration and optimization of product research and development are expected to improve the company's manufacturing automation and product competitiveness [3]. - The integration of Mindray's resources and expertise is projected to bolster the company's capabilities in electrophysiology and vascular intervention, further solidifying its market position [4].

Group 1: Strategic Partnership with Mindray Medical - Huatai Medical is introducing Mindray Medical as a strategic controlling shareholder to enhance its technological capabilities in cardiovascular fields, where it has been developing for years [3] - The domestic electrophysiology market is dominated by imported brands, holding nearly 90% market share, which highlights the need for technological improvement [3] - The partnership is expected to significantly strengthen Huatai's existing equipment, such as the 3D mapping system and radiofrequency ablation devices, accelerating the domestic market's localization rate in atrial fibrillation [3][4] Group 2: International Market Expansion - In 2022, Huatai's overseas revenue was only 136 million yuan, accounting for 11% of total revenue, indicating substantial growth potential in international markets [4] - Mindray has over 50 subsidiaries and more than 3,000 employees globally, providing a robust platform for Huatai to expand its overseas business [4] - The collaboration aims to leverage Mindray's marketing capabilities to accelerate Huatai's international business development [4] Group 3: R&D and Marketing Synergies - Mindray has over 4,400 R&D personnel, which can enhance Huatai's product performance through collaborative development [5] - The synergy between the two companies will focus on both R&D and marketing, with Mindray's extensive global market coverage benefiting Huatai's product reach [5][6] - Huatai's strong position in consumables will complement Mindray's engineering capabilities, leading to improved product quality and cost control [5] Group 4: Competitive Advantages in Cardiovascular Devices - Huatai Medical has established itself as a leader in the electrophysiology field with several first-to-market products, including the first registered domestic electrophysiology electrode catheter [6][7] - The company has a complete product line for coronary access, addressing critical clinical needs in procedures such as angiography and stent implantation [7] - In the peripheral vascular intervention sector, Huatai has gained a competitive edge with innovative products like the adjustable valve catheter sheath, which is the first of its kind in China [8] Group 5: Market Landscape and Future Prospects - The domestic electrophysiology market is still largely dominated by foreign brands, with a market share of nearly 90% for major players like Johnson & Johnson and Abbott [9] - The coronary access device market is witnessing a shift towards domestic brands, with Huatai's products gaining significant traction [9] - The peripheral vascular intervention market remains in its early stages, with foreign brands holding over 60% market share, indicating room for growth for domestic manufacturers [10] Group 6: Upcoming Product Launches - Huatai is set to launch several significant products in the vascular intervention field, including a comprehensive atrial fibrillation treatment solution that minimizes X-ray exposure during procedures [11] - The new RF ablation solution features advanced pressure sensing technology, enhancing the accuracy and stability of the ablation process [11]

深圳惠泰医疗器械股份有限公司 简式权益变动报告书 上市公司名称：深圳惠泰医疗器械股份有限公司 股票上市地点：上海证券交易所 股票简称：惠泰医疗 股票代码：688617 信息披露义务人 1：苏州工业园区启华三期投资中心（有限合伙） 执行事务合伙人：苏州启平投资管理合伙企业（有限合伙） 主要经营场所：苏州工业园区苏虹东路 183 号东沙湖股权投资中心 14 号楼 203 室 信息披露义务人 2：苏州工业园区启明融科股权投资合伙企业（有限合伙） 执行事务合伙人：苏州启平投资管理合伙企业（有限合伙） 主要经营场所：苏州工业园区苏虹东路 183 号东沙湖股权投资中心 14 号楼 203 室 信息披露义务人 3：苏州启明融盈创业投资合伙企业（有限合伙） 执行事务合伙人：苏州启平投资管理合伙企业（有限合伙） 主要经营场所：苏州市西环路 3068 号 3 号楼 111-68 室 股份变动性质：股份减少（协议转让） 签署日期：2024 年 1 月 - 1 - 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号 ...

中信证券股份有限公司 关于 深圳惠泰医疗器械股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 2024年1月 中信证券股份有限公司关于深圳惠泰医疗器械股份有限公司详式权益变动报告书之财务顾问核查意见 声 明 根据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券 的公司信息披露内容与格式准则第15号——权益变动报告书》及《公开发行证券 的公司信息披露内容与格式准则第16号——上市公司收购报告书》等法律法规和 规范性文件的规定，中信证券股份有限公司（以下简称"本财务顾问"）按照行业 公认的业务标准、道德规范，本着诚实信用、勤勉尽责的精神，对本次权益变动 的相关情况和资料进行了核查，对信息披露义务人出具的《深圳惠泰医疗器械股 份有限公司详式权益变动报告书》所披露的内容出具核查意见，以供投资者和有 关各方参考。 为此，本财务顾问特作出以下声明： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《深圳惠泰医疗器械股份有限公司详式权益变动报告书》进行了核查，确信披露 文件内容与格式符合规定，并有充分理由确信所发表的专业意见与信息披露义务 人披露的文件内容不存在实质性差异； ...